Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM CVE:BRM NASDAQ:CRDL TSE:GXE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.61-18.3%$1.03$0.46▼$7.49$10.53M-0.171.43 million shs1.32 million shsBRMBioRemC$2.22-2.2%C$2.14C$1.67▼C$3.45C$36.40M0.8573,519 shs43,596 shsCRDLCardiol Therapeutics$1.19$1.30$0.77▼$2.63$98.35M1.04310,202 shs345,885 shsGXEGear EnergyC$0.50C$0.45▼C$0.80C$126.52M3.52585,822 shs1.03 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-18.27%+70.93%+54.81%+93.67%-58.07%BRMBioRem-2.20%-6.33%+4.23%+13.27%+8.82%CRDLCardiol Therapeutics0.00%-7.75%-9.85%+17.82%-43.60%GXEGear Energy0.00%0.00%0.00%0.00%-35.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.5055 of 5 stars0.05.00.00.02.41.70.6BRMBioRemN/AN/AN/AN/AN/AN/AN/AN/ACRDLCardiol Therapeutics2.4667 of 5 stars3.73.00.00.02.70.00.6GXEGear EnergyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ABRMBioRem 0.00N/AN/AN/ACRDLCardiol Therapeutics 3.33Buy$8.00572.27% UpsideGXEGear Energy 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BRM, CRDL, APM, and GXE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K20.03N/AN/A$2.20 per share0.73BRMBioRemC$41.84M0.87C$0.60 per share3.70C$0.63 per share3.52CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AGXEGear EnergyC$134.93M0.00N/A540.00C$0.93 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)BRMBioRemC$5.40MC$0.326.86∞N/A12.91%65.14%14.61%N/ACRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)GXEGear EnergyC$13.02MC$0.0510.39N/AN/A8.53%5.08%4.84%N/ALatest BRM, CRDL, APM, and GXE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ABRMBioRemN/A6.47%N/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGXEGear EnergyC$0.0611.46%N/A120.00%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22BRMBioRem37.471.911.08CRDLCardiol Therapeutics0.013.263.26GXEGear Energy6.271.200.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%BRMBioRem0.47%CRDLCardiol Therapeutics12.49%GXEGear Energy2.42%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%BRMBioRem1.90%CRDLCardiol Therapeutics5.25%GXEGear Energy7.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableBRMBioRem34,30016.40 millionN/ANot OptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableGXEGear Energy1,310263.58 millionN/ANot OptionableBRM, CRDL, APM, and GXE HeadlinesRecent News About These CompaniesGear Energy Stock Price Today | TSX: GXE Live - Investing.comJune 27, 2025 | investing.comDon Gray Acquires 1,953,000 Shares of Gear Energy Ltd. (TSE:GXE) StockJanuary 28, 2025 | insidertrades.comInsider Buying: Gear Energy Ltd. (TSE:GXE) Senior Officer Purchases 157,500 Shares of StockDecember 28, 2024 | insidertrades.comInsider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 333,000 Shares of StockDecember 25, 2024 | insidertrades.comStocks in play: Gear Energy Ltd.December 3, 2024 | theglobeandmail.comGear Energy (GXE) Earnings Dates & ReportsNovember 6, 2024 | investing.comGear Energy: Growth AheadOctober 10, 2024 | seekingalpha.comGear Energy Ltd. (TSE:GXE) Director Scott Robinson Purchases 74,000 SharesOctober 4, 2024 | insidertrades.comDon't Buy Gear Energy Ltd. (TSE:GXE) For Its Next Dividend Without Doing These ChecksSeptember 8, 2024 | finance.yahoo.comGear Energy Ltd. (TSE:GXE) Senior Officer Sells C$71,000.00 in StockJuly 13, 2024 | insidertrades.comInsider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 192,900 Shares of StockMay 10, 2024 | insidertrades.comGear Energy Ltd. (TSE:GXE) Director Acquires C$226,765.00 in StockMay 9, 2024 | insidertrades.comGear Energy First Quarter 2024 Earnings: EPS: CA$0.01 (vs CA$0.008 in 1Q 2023)May 7, 2024 | finance.yahoo.comGear Energy Ltd. (TSE:GXE) Director Purchases C$515,015.00 in StockMay 7, 2024 | insidertrades.comHere's what Wall Street expects from Gear Energy's earnings reportMay 1, 2024 | markets.businessinsider.comInsider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 26,000 Shares of StockApril 13, 2024 | insidertrades.comIt Might Not Be A Great Idea To Buy Gear Energy Ltd. (TSE:GXE) For Its Next DividendApril 7, 2024 | finance.yahoo.comGuilty Gear Strive: Every Fighter's Skill Set And DifficultyMarch 30, 2024 | msn.comGear Energy Ltd. (TSE:GXE) Senior Officer Sells C$18,459.00 in StockMarch 23, 2024 | insidertrades.comGXE:CA Gear Energy Ltd.March 22, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRM, CRDL, APM, and GXE Company DescriptionsAptorum Group NASDAQ:APM$1.61 -0.36 (-18.27%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.56 -0.05 (-3.11%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.BioRem CVE:BRMC$2.22 -0.05 (-2.20%) As of 07/18/2025 03:59 PM EasternBioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.Cardiol Therapeutics NASDAQ:CRDL$1.19 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.21 +0.02 (+1.60%) As of 07/18/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Gear Energy TSE:GXEGear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
